Delivery Order SPE2DB22D1106-SPE2DB25FFEQ0
- Not listed
- The Defense Logistics Agency awarded a $3,818.49 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count units) on September 9, 2025, with an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the agency. The product will be performed at the vendor's Conshohocken, Pennsylvania...
- The Defense Logistics Agency awarded a $2,461.52 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets in a 30-tablet quantity, with completion scheduled for August 26, 2025. This firm fixed-price contract was competitively awarded with no set-aside designation and represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be performed and delivered from the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $35,913.34 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, which aligns with the contractor's corporate headquarters location. The award represents a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,413.45 for Ondansetron ODT 4 mg tablets (30-count supply) on August 1, 2025, with a completion date of August 4, 2025. This non-competitive, firm fixed price delivery order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a continuation of the company's extensive pharmaceutical supply relationship with DLA, supporting federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $19,783.48 to AmerisourceBergen Drug Corp on June 25, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count units). The contract is a firm fixed-price delivery order with a completion date of June 26, 2025, and is being performed at the contractor's location in Conshohocken, Pennsylvania. This award carries no set-aside designation and was competitively awarded through the federal procurement process. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $6,642.00 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitive award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a firm fixed-price transaction with no set-aside designation. The pharmaceutical will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $2,877.66 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count units) with an ultimate completion date of June 2, 2025. This non-set-aside contract represents a standard pharmaceutical supply transaction under the company's broader relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,544.42 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count package) on July 29, 2025, with completion targeted for July 30, 2025. This competitive award—utilizing firm fixed pricing with no set-aside designation—represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,227.22 for Ondansetron ODT 8 mg tablets (30-count packaging) on July 11, 2025, with an ultimate completion date of July 14, 2025. This competitively awarded, non-set-aside delivery order represents a firm fixed price transaction for pharmaceutical supply to support federal medical procurement needs. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $8,321.43 delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a completion date of June 26, 2025. This competitive award employs a firm fixed price structure with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFEQ0Delivery Order
The Defense Logistics Agency awarded a $2,487.53 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply) on August 21, 2025, with completion targeted for August 22, 2025. This firm fixed-price, non-set-aside delivery order is being performed in Conshohocken, Pennsylvania, the vendor's corporate headquarters location. The award represents a small-value transaction within AmerisourceBergen's broader pharmaceutical supply portfolio to federal customers. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), an umbrella agreement valued at $999,999,999.00 through December 2026 that enables the company to supply pharmaceutical products and medical commodities globally to support military healthcare programs. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen consistently fulfills diverse medication needs across therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through competitively awarded contracts demonstrating the company's capability to meet stringent federal supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 8/21/25 |